**Supplementary Material**

**Table 2: A.** Primers and probes used in the in-house assays specifically detecting SARS-CoV-2.

**B.** Mastermix composition and **C.** Cycling conditions.

**A. Primers and Probes**

|  |  |
| --- | --- |
| E\_ Sarbeco\_F1forward primer (WHO E-Gene) | 5’-ACAGGTACGTTAATAGTTAATAGCGT-3’ |
| E\_Sarbeco\_E2 rerverse primer (WHO E-Gene) | 5’-ATATTGCAGCAGTACGCACACA-3’ |
| E\_Sarbeco\_P1 probe (WHO E-Gene) | 5’-FAM-ACACTAGCCATCCTTACTGCGCTTCG-BHQ-3’ |
| RdRp\_SARSr-F forward primer (RdRp-Gene) | 5’-GTGARATGGTCATGTGTGGCGG-3’ |
| RdRp\_SARSr\_Rerverse primer (RdRp-Gene) | 5’-CARATGTTAAASACACTATTAGCATA-3’ |
| RdRp\_SARS-P2 probe\* (RdRp-Gene) | 5’-FAM-CAGGTGGAACCTCATCAGGAGATGC-BHQ-3’ |
| N-Forward (N-Gene) | 5’-TAATCAGACAAGGAACTGATTA-3’ |
| N-Reverse (N-Gene) | 5’-CGAAGGTGTGACTTCCATG-3’ |
| N-Probe (N-Gene) | 5’-FAM-GCAAATTGTGCAATTTGCGG-BHQ-3’ |
| China CDC-ORF1ab-Forward (ORF1ab-Gene) | CCCTGTGGGTTTTACACTTAA-3’ |
| China CDC-ORF1ab-Reverse (ORF1ab-Gene) | 5’-ACGATTGTGCATCAGCTGA-3’ |
| China CDC-ORF1ab-Probe (ORF1ab-Gene) | 5'-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ-3' |
| WMD ORF1b Forward | 5’-CATGGTGGACAGCCTTTGTTAC-3’ biosearch design set |
| WMD ORF1b Reverse | 5’-TCGCGTGGTTTGCCAAGAT-3’ |
| WMD ORF1b Probe | 5’-FAM-AATGTGAATGCGTCATCATCTGAAGCA-BHQ-3’ |
| WMD M-Gene-Forward | 5’-CAAGGACCTGCCTAAAGAAATCAC-3’ biosearch design set |
| WMD M-Gene-Reverse | 5’-ACGCTGCGAAGCTCCCAAT-3’ |
| WMD M-Gene-Probe | 5’-FAM-TGTTGCTACATCACGAACGCTTTC-BHQ-3’ |
| PCO3-Forward (hBGL-Gene) | 5’-ACACAACTGTGTTCACTAGC-3’ |
| PCO4-Reverse (hBGL-Gene) | 5’-CAACTTCATCCACGTTCACC-3’ |
| BGL-Probe (hBGL-Gene) | 5’-Quasor-TCAAACAGACACCATGGTGCACCTGA-BHQ-3’ |

\*The RdRp gene P2 probe is specific for SARS-CoV-2 and does not detect SARS-CoV [Corman].

**B. Master Mix**




AgPath-ID™ One-Step RT-PCR Kit (Applied Biosystems™ Catalog number: 4387424m)

|  |  |  |
| --- | --- | --- |
|  |  | 1x (20+5) reaction uL |
| AgPath RT mix 2x | 2x | 10 |
| Forward primer | 100 µM | 0.1 |
| Reverse primer | 100 µM | 0.1 |
| Probe (FAM/BHQ1) | 100uM | 0.05 |
| BGL PCO3 | 100uM | 0.1 |
| BGL PCO4 | 100uM | 0.1 |
| BGL probe BGL Quasar 670 | 100uM | 0.05 |
| Water |  | 4.7 |
| AgPath 25x RT enzyme | 20 µM | 0.8 |
|  |  | Total 16 |
| Sample extract |  | 4 |

**C. Cycling conditions LC480 II**

|  |  |  |  |
| --- | --- | --- | --- |
| Cycles | Temperature | Time | Ramp rate (0C/s) |
| 1x | 45 0C | 15 min | 4.4 |
| 1x | 95 0C | 15 min | 4.4 |
| 45x | 95 0C | 15 sec | 4.4 |
|  | 60 0C | 45 sec | 2.2 |
| 1x | 40 0C | 30 sec | 2.2 |

**Figure 4: Vero E6 cells infected with SARS-CoV-2**: **A**: confluent layer of Vero E6 cells with no cytopathic effect (10x magnification), **B**: Visible cytopathic effect secondary to SARS-CoV-2 replication with loss of cell layer confluence, rounding of infected cells and fusion with adjacent cells to form syncytia (10x magnification). **C**: Inset, CPE at 40x magnification.




A

B

C

**Figure 5: Mean Ct values for each target (E, M, N, ORF1ab and RdRp) for Culture positive (CPE), Culture Positive (no CPE) and Culture Negative.**



**N gene target**

|  |  |  |
| --- | --- | --- |
| ***p-values*** | **Negative** | **Positive**  **& NO CPE** |
| **Positive**  **& CPE** | **<0.001** | **0.02** |
| **Positive**  **& NO CPE** | **<0.001** |  |

**Figure 6:** **PCR Ct values by gene target comparing culture positive and culture negative upper and lower respiratory tract samples**. Lower respiratory tract samples demonstrate significantly lower Ct values than upper respiratory tract samples for N gene target (P<0.001) only.

**Figure 7:** **Comparison of days between symptom onset and sample collection for Culture Positive and Culture Negative samples (p value=<0.0001).**

